{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:57:58Z","timestamp":1782741478489,"version":"3.54.5"},"reference-count":166,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T00:00:00Z","timestamp":1437091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["IIRG\u201012\u2010239626"],"award-info":[{"award-number":["IIRG\u201012\u2010239626"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Traditional vaccination against infectious diseases relies on generation of cellular and humoral immune responses that act to protect the host from overt disease even though they do not induce sterilizing immunity. More recently, attempts have been made with mixed success to generate therapeutic vaccines against a wide range of noninfectious diseases including neurodegenerative disorders. After the exciting first report of successful vaccine prevention of progression of an Alzheimer's disease (AD) animal model in 1999, various epitope\u2010based vaccines targeting amyloid beta (A\u03b2) have proceeded to human clinical trials, with varied results. More recently, AD vaccines based on tau protein have advanced into clinical testing too. This review seeks to put perspective to the mixed results obtained so far in clinical trials of AD vaccines and discusses the many pitfalls and misconceptions encountered on the path to a successful AD vaccine, including better standardization of immunologic efficacy measures of antibodies, immunogenicity of platform\/carrier and adjuvants.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.jalz.2015.06.1884","type":"journal-article","created":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T21:28:58Z","timestamp":1437168538000},"page":"1246-1259","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease"],"prefix":"10.1002","volume":"11","author":[{"given":"Michael G.","family":"Agadjanyan","sequence":"first","affiliation":[{"name":"Department of Molecular Immunology Institute for Molecular Medicine  Huntington Beach CA USA"},{"name":"The Institute for Memory Impairments and Neurological Disorders University of California  Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[{"name":"Vaxine Pty Ltd Flinders Medical Centre  Adelaide South Australia"},{"name":"Flinders Medical Centre and Flinders University  Adelaide South Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahit","family":"Ghochikyan","sequence":"additional","affiliation":[{"name":"Department of Molecular Immunology Institute for Molecular Medicine  Huntington Beach CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,17]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2005.11928028"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03304.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0818-9641.2004.01272.x"},{"key":"e_1_2_5_5_1","first-page":"186","article-title":"Unconventional vaccines: Progress and challenges","volume":"4","author":"Petrovsky N","year":"2013","journal-title":"J\u00a0Vaccines Vaccin"},{"key":"e_1_2_5_6_1","unstructured":"U.S. Food and Drug Administration.Vaccines blood & biologics. Vaccines licensed for immunization and distribution in the US with supporting documents Available at:http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm093830.htm Accessed July 30 2015"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103293441302"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"e_1_2_5_9_1","first-page":"729","article-title":"Update on recommendations for use of herpes zoster vaccine","volume":"63","author":"Hales CM","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/2051013613515621"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"e_1_2_5_12_1","unstructured":"ReichertJM.Therapeutic monoclonal antibodies approved or in review in the European Union or United States Available at:http:\/\/www.antibodysociety.org\/news\/approved_mabs.php Accessed July 30 2015"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2015.988944"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072994"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1566067"},{"issue":"1","key":"e_1_2_5_16_1","first-page":"S67","article-title":"Molecular mechanisms of amyloid oligomers toxicity","volume":"33","author":"Kayed R","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720508784533321"},{"issue":"10","key":"e_1_2_5_18_1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006296","article-title":"The genetics of Alzheimer disease","volume":"2","author":"Tanzi RE","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E09-10-0850"},{"key":"e_1_2_5_20_1","first-page":"1192","article-title":"Review and hypothesis: Alzheimer disease and Down syndrome\u2014chromosome 21 nondisjunction may underlie both disorders","volume":"48","author":"Potter H","year":"1991","journal-title":"Am J Hum Genet"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1234"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04134.x"},{"issue":"2","key":"e_1_2_5_23_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3233\/JAD-2011-110182","article-title":"Targeting oligomers in neurodegenerative disorders: Lessons from alpha\u2010synuclein, tau, and amyloid\u2010beta peptide","volume":"24","author":"Gadad BS","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/22124"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2004.07.012"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/35050116"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4439(00)00033-8"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/35050103"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/78682"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.151261398"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn842"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-1-24"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0436286100"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/85525"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2003.09.015"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.8.4109"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(98)00098-8"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(99)00003-X"},{"key":"e_1_2_5_39_1","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1523\/JNEUROSCI.22-18-07873.2002","article-title":"Non\u2010Fc\u2010mediated mechanisms are involved in clearance of amyloid\u2010beta in\u00a0vivo by immunotherapy","volume":"22","author":"Bacskai BJ","year":"2002","journal-title":"J Neurosci"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1067568"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.00889.x"},{"key":"e_1_2_5_42_1","unstructured":"Eli Lilly and Company Announcement.Eli Lilly and Company announces top\u2010line results on solanezumab phase 3 clinical trials in\u00a0patients with Alzheimer's disease Available at:http:\/\/newsroom.lilly.com\/releasedetail.cfm?releaseid=702211 Accessed July 30 2015"},{"key":"e_1_2_5_43_1","first-page":"628070","article-title":"Targeting beta amyloid: A clinical review of immunotherapeutic approaches in Alzheimer's disease","volume":"2012","author":"Lobello K","year":"2012","journal-title":"Int J Alzheimers Dis"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12168"},{"issue":"1","key":"e_1_2_5_45_1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1471-4159.2011.07458.x","article-title":"\u2018Clinical trials in Alzheimer's disease\u2019: Immunotherapy approaches","volume":"120","author":"Delrieu J","year":"2012","journal-title":"J Neurochem"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2009.219"},{"key":"e_1_2_5_47_1","volume-title":"CAD\u2010106, a beta\u2010amyloid\u2010based immunotherapeutic for Alzheimer's disease","author":"Ghochikyan A","year":"2012"},{"issue":"1","key":"e_1_2_5_48_1","article-title":"Active and passive A\u03b2\u2010immunotherapy: Positive and negative outcomes from pre\u2010clinical and clinical trials\u00a0and future directions","volume":"8","author":"Agadjanyan MG","year":"2009","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152709787847289"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.12.020"},{"key":"e_1_2_5_51_1","unstructured":"Alzforum.Biogen antibody buoyed by phase 1 data and hungry investors.2015 Presented at the AD\/PD Conference March 25 2015"},{"key":"e_1_2_5_52_1","unstructured":"Neurimmune.Aducanumab (BIIB037) reduced brain amyloid plaque levels and slowed cognitive decline in patients with prodromal or mild Alzheimer's disease in phase 1B study. Biogen Idec presents positive interim results from phase 1B study at 2015 AD\/PD Conference\u00a02015."},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm840"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000073623.84147.A8"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2004.tb00493.x"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000148590.39911.DF"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jnen.0000240466.10758.ce"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.060269"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159740.16984.3C"},{"key":"e_1_2_5_60_1","volume-title":"Vaccine excipient & media summary. ImmunoFacts: Vaccines and immunologic drugs \u2013 2013","author":"Grabenstein J","year":"2012"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8513-4"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.033"},{"key":"e_1_2_5_63_1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3109\/00365548.2011.580777","article-title":"Explorations of clinical trials and pharmacovigilance databases of MF59(R)\u2010adjuvanted influenza vaccines for associated cases of narcolepsy","volume":"43","author":"Tsai TF","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"e_1_2_5_64_1","doi-asserted-by":"crossref","unstructured":"PetrovskyN.Comparative safety of vaccine adjuvants: a summary of current evidence and future needs.Drug Saf2015 In Press","DOI":"10.1007\/s40264-015-0350-4"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000148604.77591.67"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159743.08996.99"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm783"},{"key":"e_1_2_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61075-2"},{"key":"e_1_2_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(03)00294-0"},{"key":"e_1_2_5_70_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.280.5361.243"},{"key":"e_1_2_5_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2009.00927.x"},{"key":"e_1_2_5_72_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152709787847324"},{"key":"e_1_2_5_73_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152709787847315"},{"key":"e_1_2_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.01.031"},{"issue":"4","key":"e_1_2_5_75_1","first-page":"113","article-title":"Results of the first\u2010in\u2010man study with the active Abeta immunotherapy CAD106 in Alzheimer's patients","volume":"5","author":"Winblad BG","year":"2009","journal-title":"Alzheimers Dement"},{"key":"e_1_2_5_76_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3201-07.2007"},{"key":"e_1_2_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.12.003"},{"key":"e_1_2_5_78_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2009-1118"},{"key":"e_1_2_5_79_1","volume-title":"Janeway's Immunobiology","author":"Murphy K","year":"2008"},{"key":"e_1_2_5_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-8-36"},{"key":"e_1_2_5_81_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.883921"},{"key":"e_1_2_5_82_1","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt237"},{"key":"e_1_2_5_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3409"},{"key":"e_1_2_5_84_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.7.1.7"},{"key":"e_1_2_5_85_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0703137104"},{"key":"e_1_2_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.04.505"},{"key":"e_1_2_5_87_1","unstructured":"AlzForum.In surprise placebo not A\u03b2 vaccine said to slow Alzheimer's Available at:http:\/\/www.alzforum.org\/news\/research\u2010news\/surprise\u2010placebo\u2010not\u2010av\u2010vaccine\u2010said\u2010slow\u2010alzheimers Accessed July 30 2015"},{"key":"e_1_2_5_88_1","unstructured":"AlzForum.Vanutide cridificar Available at:http:\/\/www.alzforum.org\/therapeutics\/vanutide\u2010cridificar Accessed July 30 2015"},{"key":"e_1_2_5_89_1","unstructured":"V950\u2010001 AM7.ClinicalTrials.govIdentifier:NCT00464334.\u00a02014."},{"key":"e_1_2_5_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70140-0"},{"key":"e_1_2_5_91_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.11.13217"},{"key":"e_1_2_5_92_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205012666150302154121"},{"key":"e_1_2_5_93_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"e_1_2_5_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889"},{"issue":"1","key":"e_1_2_5_95_1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/alzrt198","article-title":"Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: Consensus from the Canadian conference on diagnosis of dementia","volume":"5","author":"Chertkow H","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"e_1_2_5_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.107"},{"key":"e_1_2_5_97_1","unstructured":"Hoffmann\u2010La Roche. A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease. Identifier:NCT01224106."},{"key":"e_1_2_5_98_1","unstructured":"DIAN study. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Identifier:NCT01760005."},{"key":"e_1_2_5_99_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007941"},{"key":"e_1_2_5_100_1","unstructured":"ADCS\/A4.NCT02008357: Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)."},{"key":"e_1_2_5_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2014.01.013"},{"key":"e_1_2_5_102_1","doi-asserted-by":"publisher","DOI":"10.1089\/rej.2006.9.77"},{"key":"e_1_2_5_103_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0381-06.2006"},{"key":"e_1_2_5_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.073"},{"key":"e_1_2_5_105_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.125"},{"key":"e_1_2_5_106_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4933-5-11"},{"key":"e_1_2_5_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2588"},{"key":"e_1_2_5_108_1","doi-asserted-by":"publisher","DOI":"10.1159\/000113700"},{"key":"e_1_2_5_109_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-015-0108-3"},{"key":"e_1_2_5_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.973"},{"key":"e_1_2_5_111_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.23875"},{"key":"e_1_2_5_112_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079469"},{"key":"e_1_2_5_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm790"},{"key":"e_1_2_5_114_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700088200"},{"key":"e_1_2_5_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2003.11.019"},{"key":"e_1_2_5_116_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3233\/JAD-120850","article-title":"Prevention of amyloid\u2010beta fibril formation using antibodies against the C\u2010terminal region of amyloid\u2010beta1\u201040 and amyloid\u2010beta1\u201042","volume":"34","author":"Montanes M","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_5_117_1","unstructured":"BergerW.Identification of subjects with a high risk of developing type I diabetes. Summary of a workshop held on May 25th 1984 in the Children's Hospital in Basel Switzerland.Bull Schweiz Akad Med Wiss1984;81\u201385"},{"key":"e_1_2_5_118_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.47.12.1857"},{"issue":"1","key":"e_1_2_5_119_1","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1177\/1740774510373496","article-title":"Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: Efforts to harmonize procedures among the laboratories","volume":"7","author":"Bingley PJ","year":"2010","journal-title":"Clin Trials"},{"key":"e_1_2_5_120_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-7560(199901\/02)15:1<72::AID-DMRR11>3.0.CO;2-G"},{"key":"e_1_2_5_121_1","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.1999.0312"},{"key":"e_1_2_5_122_1","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt278"},{"key":"e_1_2_5_123_1","unstructured":"Clinicaltrials.gov.NCT02031198: 18\u2010months safety follow\u2010up study of AADvac1 an active tau vaccine for Alzheimer's disease (FUNDAMANT). 2014. Available at:https:\/\/ct2\/show\/NCT02031198?term=Axon+Neuroscience&rank=1. Accessed July30 2015."},{"key":"e_1_2_5_124_1","unstructured":"AlzForum.ACI\u201035 Available at:http:\/\/www.alzforum.org\/therapeutics\/aci\u201035 Accessed July 30 2015"},{"key":"e_1_2_5_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2194"},{"key":"e_1_2_5_126_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720510793611592"},{"key":"e_1_2_5_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1243-9"},{"key":"e_1_2_5_128_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1162-1"},{"key":"e_1_2_5_129_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1170-1"},{"key":"e_1_2_5_130_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"e_1_2_5_131_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00688184"},{"key":"e_1_2_5_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(70)90063-8"},{"key":"e_1_2_5_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70291-0"},{"key":"e_1_2_5_134_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"key":"e_1_2_5_135_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2013.00093"},{"key":"e_1_2_5_136_1","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12044"},{"key":"e_1_2_5_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2013.07.046"},{"key":"e_1_2_5_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2786"},{"key":"e_1_2_5_139_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.209296"},{"key":"e_1_2_5_140_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031302"},{"key":"e_1_2_5_141_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100760"},{"key":"e_1_2_5_142_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-303144"},{"key":"e_1_2_5_143_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-011-9576-5"},{"key":"e_1_2_5_144_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2361-07.2007"},{"key":"e_1_2_5_145_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4363-10.2010"},{"key":"e_1_2_5_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2010.05.010"},{"key":"e_1_2_5_147_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.10.1459"},{"key":"e_1_2_5_148_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026860"},{"key":"e_1_2_5_149_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.060002"},{"key":"e_1_2_5_150_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.070345"},{"key":"e_1_2_5_151_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720512800492503"},{"key":"e_1_2_5_152_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072301"},{"key":"e_1_2_5_153_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.229633"},{"key":"e_1_2_5_154_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.346072"},{"key":"e_1_2_5_155_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3192-13.2014"},{"key":"e_1_2_5_156_1","unstructured":"Smart Patients. Safety study of AADvac1 a tau peptide\u2010KLH\u2010conjugate active vaccine to treat Alzheimer's disease; 2014. Available at:https:\/\/www.smartpatients.com\/clinical\u2010trials\/NCT01850238. Accessed July 30 2015."},{"key":"e_1_2_5_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.01.049"},{"key":"e_1_2_5_158_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20142322"},{"key":"e_1_2_5_159_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn968"},{"key":"e_1_2_5_160_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5448.2352"},{"key":"e_1_2_5_161_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/21.4.643"},{"key":"e_1_2_5_162_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871527313666140806124850"},{"key":"e_1_2_5_163_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20121274"},{"key":"e_1_2_5_164_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.12.068"},{"key":"e_1_2_5_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.11.020"},{"key":"e_1_2_5_166_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1781"},{"key":"e_1_2_5_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2005.05.010"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526015021214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526015021214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.jalz.2015.06.1884","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2015.06.1884","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.jalz.2015.06.1884","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2015.06.1884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T18:25:25Z","timestamp":1759861525000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1016\/j.jalz.2015.06.1884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,17]]},"references-count":166,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1016\/j.jalz.2015.06.1884"],"URL":"https:\/\/doi.org\/10.1016\/j.jalz.2015.06.1884","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,17]]},"assertion":[{"value":"2015-07-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}